Lukassek / Shutterstock.com
19 May 2016Europe
Bayer and ERS enter CRISPR patent licensing agreement
Bayer and ERS Genomics have signed a patent licensing agreement which gives Bayer access to ERS’s CRISPR/Cas9 genome-editing patents.
Bayer and ERS Genomics have signed a patent licensing agreement which gives Bayer access to ERS’s CRISPR/Cas9 genome-editing patents.
